Neoadjuvant chemotherapy versus chemoradiotherapy for esophageal cancer: a tradeoff between dysphagia and pathologic response

Natalie Lui


Sunde et al. reported their findings on the relief of dysphagia after neoadjuvant chemoradiotherapy versus chemotherapy in patients with esophageal cancer (1). Dysphagia was a secondary endpoint in a multicenter, randomized clinical trial, NEOadjuvant therapy in RESectable esophageal cancer (NeoRes) (2,3). They found that patients who underwent neoadjuvant chemoradiotherapy had higher rates of dysphagia, but a better pathologic response, compared to patients who underwent neoadjuvant chemotherapy.